Effects of Chronic and Intermittent Calorie Restriction on Adropin Levels in Breast Cancer

References

• Tucker MJ: The effect of long-term food restriction on tumours in rodents. Int J Cancer 23(6), 803–807, 1979.
   PubMed Web of Science ®Google Scholar
• Pariza MW: Fat, calories, and mammary carcinogenesis: net energy effects. Am J Clin Nutr 45(1 Suppl), 261–263, 1987.
   PubMed Web of Science ®Google Scholar
• Gillette CA, Zhu Z, Westerlind KC, Melby CL, Wolfe P, et al.: Energy availability and mammary carcinogenesis: effects of calorie restriction and exercise. Carcinogenesis 18(6), 1183–1188, 1997.
   PubMed Web of Science ®Google Scholar
• Dirx MJ, Zeegers MP, Dagnelie PC, van den Bogaard T, van den Brandt PA: Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis. Int J Cancer 106(5), 766–770, 2003.
   PubMed Web of Science ®Google Scholar
• Dogan S, Rogozina OP, Lokshin AE, Grande JP, Cleary MP: Effects of chronic vs. intermittent calorie restriction on mammary tumor incidence and serum adiponectin and leptin levels in MMTV-TGF-alpha mice at different ages. Oncol Lett 1(1), 167–176, 2010.
   PubMed Web of Science ®Google Scholar
• Cleary MP, Jacobson MK, Phillips FC, Getzin SC, Grande JP, et al.: Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor-alpha female mice. Cancer Epidemiol Biomarkers Prev 11(9), 836–843, 2002.
   PubMed Web of Science ®Google Scholar
• Cleary MP, Grande JP, and Maihle NJ: Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice. Int J Obes Relat Metab Disord 28(8), 956–962, 2004.
   PubMed Web of Science ®Google Scholar
• Cleary MP, Hu X, Grossmann ME, Juneja SC, Dogan S, et al.: Prevention of mammary tumorigenesis by intermittent caloric restriction: does caloric intake during refeeding modulate the response? Proc Soc Exp Biol Med 232(1), 70–80, 2007.
   Web of Science ®Google Scholar
• Mizuno NK, Rogozina OP, Seppanen CM, Liao DJ, Cleary MP, et al.: Combination of intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors. Cancer Prev Res 6(6), 540–547, 2013.
   PubMed Web of Science ®Google Scholar
• Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S, et al.: Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters. Am J Pathol 138(6), 1527–1534, 1991.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Halter SA, Holt JT, Hogan BL, and Coffey RJ: Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61(6), 1147–1155, 1990.
   PubMed Web of Science ®Google Scholar
• Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powles T, et al.: The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 67(6), 1408–1412, 1993.
   PubMed Web of Science ®Google Scholar
• Grossmann ME, Ray A, Nkhata KJ, Malakhov DA, Rogozina OP, et al.: Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 29(4), 641–653, 2010.
   PubMed Web of Science ®Google Scholar
• Aydin S, Kuloglu T, and Aydin S: Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides 47, 66–70, 2013.
   PubMed Web of Science ®Google Scholar
• Celik E, Yilmaz E, Celik O, Ulas M, Turkcuoglu I, et al.: Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med 41(4), 375–380, 2013.
   PubMed Web of Science ®Google Scholar
• Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, et al.: Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity 20(7), 1394–1402, 2012.
   PubMed Web of Science ®Google Scholar
• Kuhla A, Hahn S, Butschkau A, Lange S, Wree A, et al.: Lifelong caloric restriction reprograms hepatic fat metabolism in mice. J Gerontol A Biol Sci Med Sci 69(8), 915–922, 2014.
   PubMed Web of Science ®Google Scholar
• Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, et al.: Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 8(6), 468–481, 2008.
   PubMed Web of Science ®Google Scholar
• St-Onge MP, Shechter A, Shlisky J, Tam CS, Gao S, et al.: Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity 22(4), 1056–1063, 2014.
   PubMed Web of Science ®Google Scholar
• Nergiz S, Altinkaya SO, Kurt Omurlu I, Yuksel H, Kucuk M, et al.: Circulating adropin levels in patients with endometrium cancer. Gynecol Endocrinol 31(9), 730–735, 2015.
   PubMed Web of Science ®Google Scholar
• Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, et al.: Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab 97(10), 3783–3791, 2012.
   PubMed Web of Science ®Google Scholar
• Sayin O, Tokgoz Y, and Arslan N: Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 27(5–6), 479–484, 2014.
   PubMed Web of Science ®Google Scholar
• Demircelik B, Cakmak M, Nazli Y, Gurel OM, Akkaya N, et al.: Adropin: a new marker for predicting late saphenous vein graft disease after coronary artery bypass grafting. Clin Invest Med 37(5), E338–344, 2014.
   PubMed Web of Science ®Google Scholar
• Zhao LP, You T, Chan SP, Chen JC, and Xu WT: Adropin is associated with hyperhomocysteine and coronary atherosclerosis. Exper Ther Med 11(3), 1065–1070, 2016.
   PubMed Web of Science ®Google Scholar
• Wu L, Fang J, Chen L, Zhao Z, Luo Y, et al.: Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 52(5), 751–758, 2014.
   PubMed Web of Science ®Google Scholar
• Yu HY, Zhao P, Wu MC, Liu J, Yin W: Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept 190–191, 46–49, 2014.
   PubMed Web of Science ®Google Scholar
• Gu X, Li H, Zhu X, Gu H, Chen J, et al.: Inverse correlation between plasma adropin and ET-1 levels in essential hypertension: a cross-sectional study. Medicine 94(40), e1712, 2015.
   PubMed Web of Science ®Google Scholar
• Kume T, Calan M, Yilmaz O, Kocabas GU, Yesil P, et al.: A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest 39(7), 747–754, 2016.
   PubMed Web of Science ®Google Scholar
• Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, et al.: Adropin is a novel regulator of endothelial function. Circulation 122(11 Suppl), S185–192, 2010.
   PubMed Web of Science ®Google Scholar
• Lian W, Gu X, Qin Y, and Zheng X: Elevated plasma levels of adropin in heart failure patients. Intern Med 50(15), 1523–1527, 2011.
   PubMed Web of Science ®Google Scholar
• Yolbas S, Kara M, Yilmaz M, Aydin S, and Koca SS: Serum adropin level and ENHO gene expression in systemic sclerosis. Clin Rheumatol 35(6), 1535–1540, 2016.
   PubMed Web of Science ®Google Scholar
• Halter SA, Dempsey P, Matsui Y, Stokes MK, Graves-Deal R, et al.: Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. Am J Pathol 140(5), 1131–1146, 1992.
   PubMed Web of Science ®Google Scholar
• Arditi JD, Venihaki M, Karalis KP, and Chrousos GP: Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 39(1), 9–13, 2007.
   PubMed Web of Science ®Google Scholar
• Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, et al.: Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345(1), 271–279, 2006.
   PubMed Web of Science ®Google Scholar
• Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, and Cleary MP: Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98(2), 370–379, 2008.
   PubMed Web of Science ®Google Scholar
• Nkhata KJ, Ray A, Schuster TF, Grossmann ME, and Cleary MP: Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 21(6), 1611–1619, 2009.
   PubMed Web of Science ®Google Scholar
• Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, et al.: Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 229(1–2), 161–173, 2005.
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, et al.: Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279(2), 1304–1309, 2004.
   PubMed Web of Science ®Google Scholar